Revenue Recognition (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) item $ / shares	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Aug. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)
Revenue recognized	$ 20,900
Allowances on accounts receivable	7,259	$ 6,481	$ 3,830	$ 2,429
Other assets	36,720	15,403
Deferred revenue	$ 36,592	35,740	30,778
Product
Approximate percentage of revenue collected within 9 months	90.00%
Billing collection period (in months)	9 months
Extended billing collection period (in months)	6 months
Increased (decreased) revenues	$ 10,500
(Increased) decreased net loss per share | $ / shares	$ 0.08
Tests delivered in prior periods that were fully collected
Increased (decreased) revenues	$ 151,200	5,300	19,500
(Increased) decreased net loss	$ 151,200	$ 5,300	$ 19,500
(Increased) decreased net loss per share | $ / shares	$ 1.21	$ 0.05	$ 0.20
Amounts not refunded to insurance carriers
Increased (decreased) revenues	$ 4,200	$ 13,100	$ 5,800
(Increased) decreased net loss	$ 4,200	$ 13,100	$ 5,800
(Increased) decreased net loss per share | $ / shares	$ 0.03	$ 0.11	$ 0.06
BGI Genomics
Revenue recognized	$ 44,000		$ 0
Revenue, remaining performance obligation	6,000
Transaction price	50,000
Deferred revenue	17,300
Prepaid royalties	$ 20,000
BGI Genomics | License and related development services
Revenue recognized		$ 100	8,000
Number of performance obligations | item	2
Revenue, remaining performance obligation	$ 24,000
BGI Genomics | Sequencing services
Other assets	4,100					$ 6,000
BGI Genomics | Sequencing products
Other assets						4,000
Prepaid expenses and other current assets	800
Equipment and services received	800	5,100
BGI Genomics | Sequencing products and services
Other assets	3,300					$ 10,000
BGI Genomics | Oncology assay interpretation services
Revenue recognized	1,600	1,500
Revenue, remaining performance obligation	20,000
BGI Genomics | Royalty
Deferred revenue	1,400	1,200
Foundation Medicine ("FMI")
Revenue recognized	$ 24,300
Agreement term	5 years
Automatic renewals, successive period thereafter	1 year
Revenue, remaining performance obligation	$ 7,700
Transaction price					$ 32,000
Deferred revenue	1,700
Prepaid royalties	5,000
Foundation Medicine ("FMI") | Oncology assay interpretation services
Revenue recognized	1,500	1,000	400
Revenue, remaining performance obligation	5,000
Foundation Medicine ("FMI") | Oncology products
Revenue recognized		$ 200	$ 3,500
Revenue, remaining performance obligation	$ 19,300